Jcourse
it has nothing to do with ASX or in US. It is all about risk and reward for mid-cap pharma companies like SRX. If SRX is undervalued, big pharma will do a T/O vice versa.
A lot of holders in ASX might misinterpret the trail results, but certainly not me as I have personally overseas trials in Australia and in UK. The trails results will speak for itself. There is a reason why survival were used a a primary endpoint. People need to accept that not meeting primary endpoint in clinical trial is not something very unusual and perhaps also not the end of the world. Thus, a 12% dropped today is fair and reasonable. SRX still worth about $800-900mil which is why I was only sold 50% of my total holdings. the next 2 trails are extremely important.
DYOR
Sirt result, page-72
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.5¢ | $1.602K | 9.154K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 3847679 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 2509481 | 36 |
View Market Depth
| Last trade - 15.19pm 23/08/2024 (20 minute delay) ? |
| SRX (ASX) Chart |